GeneDx (NASDAQ:WGS) vs. Q Biomed (OTCMKTS:QBIO) Head-To-Head Contrast

GeneDx (NASDAQ:WGS) and Q Biomed (OTCMKTS:QBIO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares GeneDx and Q Biomed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GeneDx	-4.92%	14.73%	8.67%
Q Biomed	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for GeneDx and Q Biomed, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	1	0	7	1	2.89
Q Biomed	0	0	0	0	0.00

GeneDx presently has a consensus price target of $140.71, suggesting a potential upside of 112.56%. Given GeneDx’s stronger consensus rating and higher probable upside, equities research analysts clearly believe GeneDx is more favorable than Q Biomed.

Institutional and Insider Ownership

61.7% of GeneDx shares are held by institutional investors. 29.6% of GeneDx shares are held by insiders. Comparatively, 28.2% of Q Biomed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk & Volatility

GeneDx has a beta of 2.17, suggesting that its share price is 117% more volatile than the S&P 500. Comparatively, Q Biomed has a beta of 2.53, suggesting that its share price is 153% more volatile than the S&P 500.

Earnings and Valuation

This table compares GeneDx and Q Biomed”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$427.54 million	4.54	-$21.02 million	($0.75)	-88.27
Q Biomed	N/A	N/A	N/A	($0.02)	N/A

Q Biomed has lower revenue, but higher earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Q Biomed, indicating that it is currently the more affordable of the two stocks.

Summary

GeneDx beats Q Biomed on 9 of the 12 factors compared between the two stocks.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.

About Q Biomed

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.